- Britain’s NHS has an elder care problem.
- Medicare Trustees: The Part A fund will now become insolvent in 2033 — three years earlier than previous predictions.
- AEI on the latest Medicare Trustees report.
- The FDA has granted approval to 270 treatments over its 30 years. Yet they have accounted for well below 1 percent of Medicaid spending.
- MAHA may bring back whole milk for kids.
- More reasons why the FDA should require proof of safety, but not efficacy, for new drug approvals.
Category: Drug Prices & Regulations
Friday Links
- House reconciliation bill creates new subsidies for small business to help employees buy individually owned health insurance.
- How AEI would reform MA plans.
- Does exercise really help cancer survival?
- For diabetes, lifestyle changes are twice as effective as Metformin.
- Should everyone have a glucose monitor?
New Commissioner Faces Uphill Battle to Reform FDA
The Wall Street Journal reports that the new U.S. Food and Drug Administration (FDA) commissioner Marty Makary faces numerous obstacles in his plans to remake the federal agency. Dr. Makary faces a reduction in staff, plummeting staff morale, and internal criticism that he is compromising scientific standards.
Thursday Links
- “The number of those providing genuine Marcus Welby MD style primary care … continues to fall. And it’s not too hard to figure out why. The average primary doctor makes a whole lot less than their specialty counterparts.”
- Senate Finance version of the Big, Beautiful Bill: good, bad and ugly.
- Do medical licensing laws violate the right to free speech?
- Paragon Health study: There are 6.4 million ineligible enrollees with (Obamacare) exchange coverage. Note: fraud is easy if the premium is zero.
- FDA to fast track drug approval if the manufacturer is in line with Trump’s health goals (like producing drugs in this country).